Two new therapies approved for the treatment of atopic dermatitis
We are pleased to announce that two new treatments have been recently approved by the FDA for the treatment of atopic dermatitis. Oregon Medical Research Center and our patients contributed to the approval by enrolling in the pivotal studies that provided the data showing the benefits of the treatment options. We want to thank all of our patient volunteers who helped make this treatment available.
U.S. FDA Approves Pfizer’s CIBINQO® (abrocitinib) for Adults with Moderate-to-Severe Atopic Dermatitis
U.S. FDA Approves RINVOQ® (upadacitinib) to Treat Adults and Children 12 Years and Older with Refractory, Moderate to Severe Atopic Dermatitis
Dr. Andrew Blauvelt named as one of the world's most influential scientists
Each year the consulting and data analysis firm Clarivate compiles an annual list of researchers who have demonstrated significant and broad influence reflected in the publication of multiple papers frequently cited by their peers.
The 2021 list includes about 3,800 researchers in 21 scientific fields, and another 2,800 researchers identified as having exceptional performance across several fields. The citation analysis considered only papers in journals indexed in the Web of Science Core Collection during the period from 2010 to 2020. Highly cited papers are defined as those that rank in the top 1% by citations for field and publication year. The method, papers weighed against others in the same annual cohort, is intended to remove the citation advantage of older papers relative to recently published ones.
Dr. Blauvelt's ranking recognizes his ongoing dedication and expertise in psoriasis research.